Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Astellas tops expectations as Vyloy sales surge outshines trial setback

Astellas tops expectations as Vyloy sales surge outshines trial setback

  • February 5, 2026

Astellas surpassed market expectations in its third-quarter fiscal year 2025 results, as first-in-class cancer drug Vyloy defied a trial setback to deliver quadrupled sales.

Leave A Comment

Fields (*) Mark are Required